vs
GLOBUS MEDICAL INC（GMED）与HAEMONETICS CORP（HAE）财务数据对比。点击上方公司名可切换其他公司
GLOBUS MEDICAL INC的季度营收约是HAEMONETICS CORP的2.4倍（$826.4M vs $339.0M），GLOBUS MEDICAL INC净利率更高（17.0% vs 13.2%，领先3.8%），GLOBUS MEDICAL INC同比增速更快（25.7% vs -2.7%），GLOBUS MEDICAL INC自由现金流更多（$202.4M vs $87.2M），过去两年GLOBUS MEDICAL INC的营收复合增速更高（16.7% vs 0.4%）
Globus Medical是总部位于美国宾夕法尼亚州奥杜邦的上市骨科医疗器械企业，专注于相关产品的设计、研发与商业化，助力外科医生为肌肉骨骼系统疾病患者提供治疗方案，促进患者康复。
豪洛捷（Haemonetics）是全球血液与血浆供应及服务提供商，于20世纪70年代由艾伦·（杰克）·莱瑟姆博士在马萨诸塞州内蒂克创立，业务围绕血液相关产品及配套服务展开，为全球医疗领域提供血液管理相关的专业解决方案。
GMED vs HAE — 直观对比
营收规模更大
GMED
是对方的2.4倍
$339.0M
营收增速更快
GMED
高出28.5%
-2.7%
净利率更高
GMED
高出3.8%
13.2%
自由现金流更多
GMED
多$115.2M
$87.2M
两年增速更快
GMED
近两年复合增速
0.4%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $826.4M | $339.0M |
| 净利润 | $140.6M | $44.7M |
| 毛利率 | 68.4% | 59.7% |
| 营业利润率 | 20.5% | 19.9% |
| 净利率 | 17.0% | 13.2% |
| 营收同比 | 25.7% | -2.7% |
| 净利润同比 | 430.4% | 19.3% |
| 每股收益（稀释后） | $1.01 | $0.95 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMEDHAE
| Q4 25 | $826.4M | $339.0M | ||
| Q3 25 | $769.0M | $327.3M | ||
| Q2 25 | $745.3M | $321.4M | ||
| Q1 25 | $598.1M | $330.6M | ||
| Q4 24 | $657.3M | $348.5M | ||
| Q3 24 | $625.7M | $345.5M | ||
| Q2 24 | $629.7M | $336.2M | ||
| Q1 24 | $606.7M | — |
净利润GMEDHAE
| Q4 25 | $140.6M | $44.7M | ||
| Q3 25 | $119.0M | $38.7M | ||
| Q2 25 | $202.8M | $34.0M | ||
| Q1 25 | $75.5M | $58.0M | ||
| Q4 24 | $26.5M | $37.5M | ||
| Q3 24 | $51.8M | $33.8M | ||
| Q2 24 | $31.8M | $38.4M | ||
| Q1 24 | $-7.1M | — |
毛利率GMEDHAE
| Q4 25 | 68.4% | 59.7% | ||
| Q3 25 | 67.2% | 59.5% | ||
| Q2 25 | 66.6% | 59.8% | ||
| Q1 25 | 67.3% | 58.4% | ||
| Q4 24 | 59.9% | 55.5% | ||
| Q3 24 | 56.8% | 54.2% | ||
| Q2 24 | 58.7% | 52.0% | ||
| Q1 24 | 60.2% | — |
营业利润率GMEDHAE
| Q4 25 | 20.5% | 19.9% | ||
| Q3 25 | 17.9% | 17.9% | ||
| Q2 25 | 10.2% | 16.8% | ||
| Q1 25 | 16.2% | 21.6% | ||
| Q4 24 | 9.2% | 16.9% | ||
| Q3 24 | 7.7% | 15.0% | ||
| Q2 24 | 7.9% | 11.8% | ||
| Q1 24 | 1.3% | — |
净利率GMEDHAE
| Q4 25 | 17.0% | 13.2% | ||
| Q3 25 | 15.5% | 11.8% | ||
| Q2 25 | 27.2% | 10.6% | ||
| Q1 25 | 12.6% | 17.5% | ||
| Q4 24 | 4.0% | 10.8% | ||
| Q3 24 | 8.3% | 9.8% | ||
| Q2 24 | 5.0% | 11.4% | ||
| Q1 24 | -1.2% | — |
每股收益（稀释后）GMEDHAE
| Q4 25 | $1.01 | $0.95 | ||
| Q3 25 | $0.88 | $0.81 | ||
| Q2 25 | $1.49 | $0.70 | ||
| Q1 25 | $0.54 | $1.17 | ||
| Q4 24 | $0.19 | $0.74 | ||
| Q3 24 | $0.38 | $0.66 | ||
| Q2 24 | $0.23 | $0.74 | ||
| Q1 24 | $-0.05 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $557.2M | $363.4M |
| 总债务越低越好 | — | $1.2B |
| 股东权益账面价值 | $4.6B | $911.5M |
| 总资产 | $5.3B | $2.5B |
| 负债/权益比越低杠杆越低 | — | 1.34× |
8季度趋势，按日历期对齐
现金及短期投资GMEDHAE
| Q4 25 | $557.2M | $363.4M | ||
| Q3 25 | $18.8M | $296.4M | ||
| Q2 25 | — | $292.9M | ||
| Q1 25 | — | $306.8M | ||
| Q4 24 | $890.1M | $320.8M | ||
| Q3 24 | $71.9M | $299.3M | ||
| Q2 24 | $82.5M | $344.4M | ||
| Q1 24 | $80.4M | — |
总债务GMEDHAE
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益GMEDHAE
| Q4 25 | $4.6B | $911.5M | ||
| Q3 25 | $4.4B | $849.2M | ||
| Q2 25 | $4.3B | $882.3M | ||
| Q1 25 | $4.1B | $820.8M | ||
| Q4 24 | $4.2B | $906.9M | ||
| Q3 24 | $4.1B | $878.9M | ||
| Q2 24 | $4.0B | $905.4M | ||
| Q1 24 | $3.9B | — |
总资产GMEDHAE
| Q4 25 | $5.3B | $2.5B | ||
| Q3 25 | $5.1B | $2.4B | ||
| Q2 25 | $5.0B | $2.5B | ||
| Q1 25 | $4.7B | $2.5B | ||
| Q4 24 | $5.3B | $2.5B | ||
| Q3 24 | $5.1B | $2.5B | ||
| Q2 24 | $5.0B | $2.5B | ||
| Q1 24 | $4.9B | — |
负债/权益比GMEDHAE
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $248.6M | $93.6M |
| 自由现金流经营现金流 - 资本支出 | $202.4M | $87.2M |
| 自由现金流率自由现金流/营收 | 24.5% | 25.7% |
| 资本支出强度资本支出/营收 | 5.6% | 1.9% |
| 现金转化率经营现金流/净利润 | 1.77× | 2.09× |
| 过去12个月自由现金流最近4个季度 | $588.8M | $308.1M |
8季度趋势，按日历期对齐
经营现金流GMEDHAE
| Q4 25 | $248.6M | $93.6M | ||
| Q3 25 | $249.7M | $111.3M | ||
| Q2 25 | $77.9M | $17.4M | ||
| Q1 25 | $177.3M | $116.6M | ||
| Q4 24 | $210.3M | $43.8M | ||
| Q3 24 | $203.7M | $48.8M | ||
| Q2 24 | $54.3M | $-27.4M | ||
| Q1 24 | $52.4M | — |
自由现金流GMEDHAE
| Q4 25 | $202.4M | $87.2M | ||
| Q3 25 | $213.9M | $106.3M | ||
| Q2 25 | $31.3M | $13.6M | ||
| Q1 25 | $141.2M | $100.9M | ||
| Q4 24 | $193.2M | $35.2M | ||
| Q3 24 | $161.7M | $39.4M | ||
| Q2 24 | $26.5M | $-33.1M | ||
| Q1 24 | $23.8M | — |
自由现金流率GMEDHAE
| Q4 25 | 24.5% | 25.7% | ||
| Q3 25 | 27.8% | 32.5% | ||
| Q2 25 | 4.2% | 4.2% | ||
| Q1 25 | 23.6% | 30.5% | ||
| Q4 24 | 29.4% | 10.1% | ||
| Q3 24 | 25.8% | 11.4% | ||
| Q2 24 | 4.2% | -9.8% | ||
| Q1 24 | 3.9% | — |
资本支出强度GMEDHAE
| Q4 25 | 5.6% | 1.9% | ||
| Q3 25 | 4.7% | 1.5% | ||
| Q2 25 | 6.2% | 1.2% | ||
| Q1 25 | 6.0% | 4.7% | ||
| Q4 24 | 2.6% | 2.5% | ||
| Q3 24 | 6.7% | 2.7% | ||
| Q2 24 | 4.4% | 1.7% | ||
| Q1 24 | 4.7% | — |
现金转化率GMEDHAE
| Q4 25 | 1.77× | 2.09× | ||
| Q3 25 | 2.10× | 2.88× | ||
| Q2 25 | 0.38× | 0.51× | ||
| Q1 25 | 2.35× | 2.01× | ||
| Q4 24 | 7.94× | 1.17× | ||
| Q3 24 | 3.93× | 1.44× | ||
| Q2 24 | 1.71× | -0.71× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMED
| Other | $391.8M | 47% |
| Nevro Merger Agreement | $293.6M | 36% |
| Enabling Technologies | $141.0M | 17% |
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
